+
 
For the best experience, open
m.thewire.in
on your mobile browser or Download our App.
You are reading an older article which was published on
Feb 22, 2022

Watch | Did India Lose the Chance to Be the World’s Pharma Hub During COVID?

Mitali Mukherjee and Neeta Sanghi discuss if India seized the opportunity to be the most important key to vaccine supply worldwide – especially for lower-income countries.
Mitali Mukherjee and Neeta Sanghi. Photo: The Wire
Support Free & Independent Journalism

Good morning, we need your help!

Since 2015, The Wire has fearlessly delivered independent journalism, holding truth to power.

Despite lawsuits and intimidation tactics, we persist with your support. Contribute as little as ₹ 200 a month and become a champion of free press in India.

In January this year, countries across the world have together administered over 10 billion doses. No mean feat when you consider that we’ve hit this mark just a year after the first COVID vaccine was given in the UK. What seems unclear is what India’s plan now is, on issues like booster shots for the general public, vaccines for children below 12 or the option of alternate vaccines. What also needs some introspection is whether India truly seized the moment where it could have been the most important key to vaccine supply worldwide – especially for lower-income countries struggling with the inequity of the situation. Mitali Mukherjee spoke with Neeta Sanghi, an independent supply chain consultant with thre decades of experience in the pharmaceutical business on all these issues.

Make a contribution to Independent Journalism
facebook twitter